Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exercise of the employee options would add common shares and dilute existing holders.

Rhea-AI Summary

Korro Bio (KRRO) granted stock options covering 4,000 shares to two newly hired employees, effective October 14, 2026. The exercise price is $8.88 per share, matching the Nasdaq closing price on the effective date. The options have a ten-year term and vest over four years: 25% on each employee’s first start-date anniversary, followed by 36 equal monthly installments for the remaining 75%, subject to continued service.

The independent Compensation Committee approved the grants under the 2026 Inducement Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 4,000 common shares at an $8.88 exercise price create potential dilution if exercised.

Key Figures

Options granted: 4,000 shares Exercise price: $8.88 per share Option term: 10 years +3 more

Options granted

4,000 shares

Aggregate grant to two newly hired employees

Exercise price

$8.88 per share

Grant effective date: October 14, 2026

Option term

10 years

Each option

Vesting period

4 years

Subject to continued service

Initial vesting

25%

On the first anniversary of each employee’s applicable start date

Remaining vesting

75% in 36 equal monthly installments

After the first-anniversary vesting

Key Terms

exercise price, oligonucleotide, mrna, adar proteins

4 terms

exercise price financial

"at an exercise price of $8.88 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

oligonucleotide medical

"a novel oligonucleotide promoted editing of RNA"

A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.

mrna technical

"modify the targeted native mRNA transcript"

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

adar proteins medical

"through ADAR proteins (Adenosine Deaminases Acting on RNA)"

Proteins in the ADAR family are enzymes that chemically edit RNA by changing specific adenosine letters into inosine, which cells read as guanosine; this editing can alter how genes are expressed without changing the underlying DNA. Investors care because ADAR activity is central to some drug and diagnostic strategies—like RNA therapeutics, biomarkers, and gene‑editing platforms—so discoveries or regulatory changes around ADARs can affect the value and risk of related biotech programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, October 14, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.

These grants were approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and were made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information  

Investor & Media Contact
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Korro Bio grant to new employees?

Korro Bio granted two newly hired employees nonstatutory stock options to purchase an aggregate of 4,000 common shares at $8.88 per share, effective October 14, 2026. The exercise price matched the Nasdaq closing share price on that date.

When do Korro Bio’s October 2026 employee stock options vest?

The options vest over four years, with 25% vesting on each employee’s first start-date anniversary and the remaining 75% in 36 equal monthly installments thereafter. Vesting requires continued service through each applicable vesting date. Each option has a ten-year term.